Psilocybin-assisted therapy may help treat post-traumatic stress disorder (PTSD), which current treatments often fail to relieve, especially in U.S. military veterans. This open-label pilot study will test two psilocybin doses (15 mg and 25 mg) combined with psychotherapy in 15 veterans with severe, treatment-resistant PTSD. The primary safety outcome tracks adverse events and suicidal ideation; the primary PTSD outcome uses the Clinician Administered PTSD Scale-5. Follow-up continues for 6 months after the second session. Results will be published in a peer-reviewed journal.
Among a sample of 180 American psychiatrists (mean age 48.4, 65.5% male, 24.1% trainees), about one-third (32.8%) reported personal use of and social connection to psychedelics. Psychiatrists with such personal connection tended to be younger and have fewer years of practice. Those with personal and social connection were more likely to disagree that using illegal drugs is morally wrong, that users should go to prison, are weak-minded, have no future, are poorly educated, are dishonest, or make them angry. Personal and social proximity to psychedelics is associated with less stigma toward drug use and people who use drugs.